Gruber Christian, Gruber Doris
Department of Gynecological Endocrinology and Reproductive Medicine, University of Vienna Medical School, A-1090 Vienna, Wahringer Gurtel 18-20, Austria.
Curr Opin Investig Drugs. 2004 Oct;5(10):1086-93.
Bazedoxifene is a tissue-specific selective estrogen receptor modulator being developed by Wyeth Pharmaceuticals (formerly Wyeth-Ayerst Laboratories) to be used alone for the prevention and treatment of osteoporosis in postmenopausal women and in combination with Premarin for menopausal symptoms. As of March and June 2004, worldwide phase III trials for bazedoxifene, and bazedoxifene in combination with Premarin, were ongoing.
巴泽多昔芬是惠氏制药公司（前身为惠氏-艾尔斯特实验室）正在研发的一种组织特异性选择性雌激素受体调节剂，拟单独用于预防和治疗绝经后女性的骨质疏松症，并与结合雌激素联合用于治疗更年期症状。截至2004年3月和6月，巴泽多昔芬以及巴泽多昔芬与结合雌激素联合用药的全球III期试验正在进行中。
